J Korean Med Sci.  2006 Dec;21(6):1037-1040. 10.3346/jkms.2006.21.6.1037.

Efficacy of Two Triple Eradication Regimens in Children with Helicobacter pylori Infection

• Choi J
• Jang JY
• Kim JS
• Park HY
• Choe YH
• Kim KM

• KMID: 1713115
• DOI: http://doi.org/10.3346/jkms.2006.21.6.1037

Abstract

Triple therapy with bismuth subsalicylate, amoxicillin, metronidazole (BAM) or with omeprazole, amoxicillin, clarithromycin (OAC) has been commonly used for the eradication of Helicobacter pylori infection. We compared the efficacy of these triple therapies in children with H. pylori infection. We retrospectively analyzed results in 233 children with H. pylori infection and treated with OAC (n=141) or BAM (n=92). Overall eradication rates of triple therapy with OAC and BAM were 74% and 85%, respectively, which showed no statistical difference. Our study showed that the triple therapy with BAM was more effective for the first-line eradication of H. pylori infection in Korean children, but has no statistical difference with OAC regimen.

Keyword

Helicobacter pylori, Treatment Outcome, Child; bismuth subsalicylate; Amoxicillin; Metronidazole

MeSH Terms

Treatment Outcome
Salicylates/*administration & dosage
Retrospective Studies
Organometallic Compounds/*administration & dosage
Omeprazole/*administration & dosage
Metronidazole/*administration & dosage
Male
Humans
Helicobacter pylori/*drug effects
Helicobacter Infections/*drug therapy
Female
Drug Combinations
Clarithromycin/*administration & dosage
Child, Preschool
Child
Bismuth/*administration & dosage
Anti-Bacterial Agents/administration & dosage
Amoxicillin/*administration & dosage
Adolescent

Figure

• 

  Fig. 1 Treatment strategies and outcomes of the study population. OAC, omeprazole+amoxicillin+clarithromycin; BAM, bismuth subsalicylate+amoxicillin+metronidazole; UBT, urea breath test.

Reference

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithleium in active chronic gastritis. Lancet. 1983. 1:1273–1275.

2. Kim KM, Oh YL, Ko JS, Choe YH, Seo JK. Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis. J Gastroenterol. 2004. 39:231–237.

3. Kim KM, Oh YL, Seo JK. Analysis of genes of Helicobacter pylori and relationship to histopathology, cyclooxygenase-2, and Ki-67 expression in Korean children. Helicobacter. 2004. 9:550(A).

4. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002. 16:167–180.

5. Gold BD, Colletti RB, Abbott M, Czinn SJ, Elitsur Y, Hassall E, Macarthur C, Snyder J, Sherman PM. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2000. 31:490–497.

6. Kalach N, Bergeret M, Benhamou PH, Dupont C, Raymond J. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol. 2001. 39:394–397.

7. Crone J, Granditsch G, Huber WD, Binder C, Innerhofer A, Amann G, Hirschl AM. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr. 2003. 36:368–371.

8. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004. 53:1374–1384.

9. Bae SH, Koh JS, Seo JK. Therapeutic efficacy of dual therapy and triple therapy for Helicobacter pylori infection in children. J Korean Pediatr Soc. 1997. 41.

10. Choi IK, Lee SY, Chung KS. Effect of one- or two-week triple therapy with omeprazole, amoxicillin, and clarithromycin on eradication of Helicobacter pylori infection in children. Korean J Pediatr Gastroenterol Nutr. 2002. 5:19–25.

11. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group [published erratum appears in Gut 1997 Aug; 41(2): 276]. Gut. 1997. 41:8–13.

12. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998. 13:1–12.

13. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994. 272:65–69.

14. Rerksuppaphol S, Hardikar W, Midolo PD, Ward P. Antimicrobial resistance in Helicobacter pylori isolates from children. J Paediatr Child Health. 2003. 39:332–335.

15. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J, Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004. 10:1088–1094.

16. Ko JS, Yang HR, Seo JK. Detection of 23S rRNA mutation associated with clarithromycin resistance in children with Helicobacter pylori infection. Korean J Pediatr Gastroenteril Nutr. 2004. 7:137–142.

17. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004. 48:4843–4847.

18. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, Lopes AI, Ramalho P, Neves BC, Guerreiro AS. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother. 2000. 46:1029–1031.

19. Goh KL. Update on the management of Helicobacter pylori infection, including drug-resistant organisms. J Gastroenterol Hepatol. 2002. 17:482–487.

20. Czinn SJ. Helicobacter pylori infection: detection, investigation, and management. J Pediatr. 2005. 146:Suppl 3. S21–S26.

21. Taneike I, Goshi S, Tamura Y, Wakisaka-Saito N, Matsumori N, Yanase A, Shimizu T, Yamashiro Y, Toyoda S, Yamamoto T. Emergence of clarithromycin-resistant Helicobacter pylori (CRHP) with a high prevalence in children compared with their parents. Helicobacter. 2002. 7:297–305.

22. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother. 1999. 43:511–515.

23. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther. 2001. 15:1473–1478.

24. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001. 161:1217–1220.

25. Torres J, Camorlinga-Ponce M, Perez-Perez G, Madrazo-De la Garza A, Dehesa M, Gonzalez-Valencia G, Munoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001. 39:2677–2680.

26. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari FA, Graham DY, Kwon DH. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000. 44:2214–2216.

27. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol. 1999. 34:750–756.

28. Isomoto H, Inoue K, Furusu H, Enjoji A, Fujimoto C, Yamakawa M, Hirakata Y, Omagari K, Mizuta Y, Murase K, Shimada S, Murata I, Kohno S. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003. 18:101–107.

29. Farup PG, Tholfsen J, Wetternus S, Torp R, Hoie O, Lange OJ. Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scand J Gastroenterol. 2002. 37:1374–1379.